Mankind Pharma cuts consumer outlook to single-digit growth
Key highlights
- Mankind Pharma lowered its FY27 consumer-health growth outlook to single digits after growth slowed from 15% in FY25 to 9% in FY26 and 2.6% in H1 FY27.
- Consumer-health revenue was Rs 229 crore in Q2 FY27, while total revenue from operations rose 17.3% year on year to Rs 4,338 crore.
- E-commerce accounted for around 15% of consumer-business sales and was growing 100%, while modern trade and e-commerce together represented 18% of consumer-health sales.
- Mankind Pharma’s management expects consumer health to return to the right track in FY28 but has not provided a numerical growth target.
powered by IRIS

Mankind Pharma Limited expects consumer-health growth to be in single digits in FY27 after the segment grew 2.6% in H1 FY27 and generated Rs 229 crore in Q2 FY27. Management cited slower category offtake and disruption in eastern and southern India, while planning leadership changes and placing greater emphasis on e-commerce.
Know Mankind Pharma inside out
Results, valuation, peers and who's buying, in one view.
Why did Mankind Pharma cut its consumer-health growth outlook?
Mankind Pharma cut its FY27 consumer-health outlook to single-digit growth because the business has fallen short of management’s expectations. On the October 26, 2026 earnings call, Vice Chairman and Managing Director Rajeev Juneja said management was unhappy with consumer-business performance when asked whether the earlier high-single-digit to low-double-digit expectation still applied.
The slowdown has been progressive across reported periods. Consumer-health growth was 15% in FY25, declined to 9% in FY26 and then slowed to 2.6% in H1 FY27. Q2 FY27 revenue from the segment was Rs 229 crore, with management attributing the outcome to slower industry category offtake and regional effects in the East and South.
The revised view contrasts with the wider domestic business, which grew 14.8% year on year to Rs 3,657 crore in Q2 FY27. Management said that result reflected 16% growth in core domestic operations excluding consumer health and mid-teen growth in BSV domestic business, leaving consumer health as the stated area of underperformance.
What caused Mankind Pharma's consumer-health slowdown?
Mankind Pharma said slower category offtake and regional effects in eastern and southern India affected Q2 FY27 consumer-health revenue of Rs 229 crore. Management did not disclose the sales impact attributable to either region, identify the affected product categories, or provide a separate measure of industry category growth.
The company said it nevertheless gained market share in Manforce and Preganews during the quarter. It did not provide market-share percentages or revenue for either brand, so the call does not establish whether those share gains offset sales declines in other consumer products.
The consumer trend differs from several other reported businesses. Hospital revenue rose 23% year on year in Q2 FY27, international revenue increased 33% to Rs 680 crore, and total revenue from operations grew 17.3% to Rs 4,338 crore. Management therefore presented the consumer-health issue as specific to that segment rather than as a reduction in overall company revenue expectations.
How is Mankind Pharma changing its consumer-health business?
Mankind Pharma plans to build a more robust consumer-health leadership team over the next couple of months. Juneja said the business would see transformative changes similar to those previously made in the wider company, but management did not disclose appointments, a revised organisational structure or the cost of the planned changes.
E-commerce and quick commerce are central to the stated response. During the question-and-answer session, management said e-commerce was growing 100% and accounted for around 15% of consumer-business sales. In prepared remarks, it said modern trade and e-commerce together represented 18% of consumer-health sales, compared with 12% a year earlier, supported by 55% growth in the combined channel.
The call did not reconcile the 100% e-commerce growth figure with the 55% growth reported for modern trade and e-commerce together, nor did it provide channel revenue in rupees. Management said its thrust would be toward e-commerce while the leadership team is rebuilt, indicating that channel expansion is intended to support recovery beyond the single-digit FY27 expectation.
Got a follow-up? Ask IRIS
Can Mankind Pharma return consumer health to faster growth?
Mankind Pharma management said it expects consumer health to return to the right track in FY28, but it gave no numerical FY28 growth target. When asked whether the segment could recover in FY28, Juneja answered affirmatively, making this a management expectation rather than quantified guidance.
Management’s product approach includes moving selected prescription products into the consumer-health business after they become over-the-counter, or OTC, products. It cited HealthOK and AcneStar as examples and identified Gas-O-Fast as a product performing well, while saying other products were being considered without naming them or providing transfer dates.
Juneja said the success rate for newly launched consumer products is in single digits and that more than 90% can fail. That disclosed risk helps explain management’s use of products with an existing prescription-side presence, but the call gave no expected revenue contribution from HealthOK, AcneStar, Gas-O-Fast or future product transfers.
How does consumer health compare with Mankind Pharma's core business?
Mankind Pharma’s consumer-health growth of 2.6% in H1 FY27 lagged its core domestic and specialty businesses. Domestic revenue excluding consumer healthcare rose 15.9% year on year to Rs 3,428 crore in Q2 and H1 FY27, while the company said both Mankind and BSV specialty businesses recorded double-digit growth.
The Indian pharmaceutical market, or IPM, comparison also shows broader prescription-business momentum. According to IQVIA data cited by management, Mankind Pharma’s secondary sales grew 15.7% in Q2 FY27, compared with 14.2% for the IPM excluding tirzepatide. The company’s volume growth rose from 0.5% in FY25 to 2.3% in FY26, 4.7% in Q1 FY27 and 6.2% in Q2 FY27.
Chronic therapies were another differentiator from consumer health. Mankind Pharma said chronic therapies excluding BSV accounted for 37.4% of sales in Q2 FY27, up 80 basis points year on year, supported by 19% growth in cardiac therapies and 16% growth in anti-diabetic therapies. Management’s consumer turnaround therefore sits alongside a domestic strategy focused on chronic, specialty, hospital and digital channels.
Conclusion
Mankind Pharma has reset consumer-health expectations to single-digit growth for FY27 after growth declined from 15% in FY25 to 9% in FY26 and 2.6% in H1 FY27. The Rs 229 crore Q2 FY27 consumer result lagged domestic revenue growth of 14.8%, hospital growth of 23% and international growth of 33%, even though Manforce and Preganews gained market share.
The next disclosed milestones are the leadership-team build planned over the next couple of months and the performance of e-commerce, which management said was growing 100% and contributed about 15% of consumer-business sales. Management expects the segment to recover in FY28, but has not provided an FY28 growth target, named leadership appointments or quantified revenue from planned OTC product transfers.


